Online Inquiry
Tozasertib (VX-680, MK-0457)
SPC-02243
CAS No. 639089-54-6
| Size | Price |
| 10 mM (1 mL in DMSO) | Online Inquiry |
| 25 mg | Online Inquiry |
| 100 mg | Online Inquiry |
| 250 mg | Online Inquiry |
| Bulk Size | Online Inquiry |
Aurora Kinase inhibitor ; FLT3 inhibitor ; Bcr-Abl inhibitor ; Autophagy activator
| Description |
|---|
| Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. The only exceptions are Fms-related tyrosine kinase-3 (FLT-3) and c-ABL tyrosine kinase, which are inhibited by the Tozasertib with Ki of 30 nM and 20 nM, respectively. Tozasertib induces apoptosis and autophagy. Phase 2. |
| Product Details | |
|---|---|
| CAS No. | CAS No. 639089-54-6 |
| Description | Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. The only exceptions are Fms-related tyrosine kinase-3 (FLT-3) and c-ABL tyrosine kinase, which are inhibited by the Tozasertib with Ki of 30 nM and 20 nM, respectively. Tozasertib induces apoptosis and autophagy. Phase 2. |
| Formula | C23H28N8OS |
| Molecular Weight | 464.59 |
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
| Synonyms | N/A |
| SMILES | CC1=CC(=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C |
| Solubility | DMSO |
| Usage | |
|---|---|
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.